Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).
Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, Boudreaux J, Neufeld EJ, Kenney K, Grant A, Thompson AA; CDC Thalassemia Investigators. Vichinsky E, et al. Among authors: coates t. Transfusion. 2014 Apr;54(4):972-81; quiz 971. doi: 10.1111/trf.12348. Epub 2013 Jul 25. Transfusion. 2014. PMID: 23889533 Free PMC article.
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators. Vichinsky E, et al. Among authors: coates t. Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x. Br J Haematol. 2007. PMID: 17233848 Free PMC article. Clinical Trial.
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF. Cappellini MD, et al. Among authors: coates t. Clin Ther. 2007 May;29(5):909-917. doi: 10.1016/j.clinthera.2007.05.007. Clin Ther. 2007. PMID: 17697909 Clinical Trial.
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF. Vichinsky E, et al. Among authors: coates t. Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11. Acta Haematol. 2008. PMID: 18408362 Clinical Trial.
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Vichinsky E, Olivieri N, Alberti D, Holland J, Harmatz P; Thalassemia Clinical Research Network. Walter PB, et al. Among authors: coates t. Haematologica. 2008 Jun;93(6):817-25. doi: 10.3324/haematol.11755. Epub 2008 May 10. Haematologica. 2008. PMID: 18469351 Free article. Clinical Trial.
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.
Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, Hilliard L, Kutlar A, McClain KL, Olivieri NF, Porter JB, Vichinsky EP; Multi-Center Iron Overload Research Group. Fung EB, et al. Transfusion. 2008 Sep;48(9):1971-80. doi: 10.1111/j.1537-2995.2008.01775.x. Epub 2008 May 29. Transfusion. 2008. PMID: 18513257 Free PMC article.
754 results